409 related articles for article (PubMed ID: 15820919)
1. [News in therapeutic management of chronic lymphoid leukemia].
Michallet AS; Salles G; Coiffier B; Michallet M
Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
5. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
6. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Abbott BL
Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
8. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia.
Winkler D; Döhner H; Stilgenbauer S
Curr Drug Targets; 2006 Oct; 7(10):1313-27. PubMed ID: 17073593
[TBL] [Abstract][Full Text] [Related]
9. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
12. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
Tam CS; Shanafelt TD; Wierda WG; Abruzzo LV; Van Dyke DL; O'Brien S; Ferrajoli A; Lerner SA; Lynn A; Kay NE; Keating MJ
Blood; 2009 Jul; 114(5):957-64. PubMed ID: 19414856
[TBL] [Abstract][Full Text] [Related]
13. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Krejci M; Doubek M; Brychtova Y; Stehlikova O; Chovancova J; Tichy B; Francova HS; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
Ann Hematol; 2013 Jan; 92(2):249-54. PubMed ID: 23014659
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
16. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
[TBL] [Abstract][Full Text] [Related]
18. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
[TBL] [Abstract][Full Text] [Related]
19. Treatment of fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ
Cancer; 2009 Jul; 115(13):2824-36. PubMed ID: 19402170
[TBL] [Abstract][Full Text] [Related]
20. [New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].
Telek B; Rejto L; Kiss A; Méhes L; Batár P; Udvardy M
Orv Hetil; 2004 Aug; 145(35):1795-800. PubMed ID: 15493222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
